A Framingham life sciences firm will receive a grant to work with partner firms in Israel, thanks to a second round of funding under the Massachusetts-Israel Innovation Partnership (MIIP).
According to the Massachusetts Life Sciences Center (MLSC), Bio-Tree Systems will work with Harlan Laboratories to develop a market application to increase the safety of existing drug toxicology assessing tools and methods.
Bio-Tree will receive $250,000 from the MLSC and Harlan will receive funding from the Office of the Chief Scientist in Israel.
Bio-Tree, incorporated in 2003, develops medical imaging application software that analyzes blood vessel trees, vascular networks, and other tubular networks in human body. Harlan provides services related to biological and pharmaceutical research.
“Receiving funding through MIIP lends tremendous credibility to the field we are pioneering —Vasculomics — as an up-and-coming platform for early detection of toxic compounds,” said Bio-Tree President and CEO Raul Brauner. “This grant will enable us to build an alliance with Harlan Laboratories, a global (contract research organization), and through them achieve a global reach, starting with Vasculomics’ deployment in Israel during early-mid 2014 and subsequently in Massachusetts mid-late 2014, perhaps earlier.”
MIIP, launched in June 2011, supports innovation and entrepreneurship between Massachusetts’ and Israel’s life sciences, clean energy and technology sectors and has a total annual R&D budget of $2 million.
